Structured evidence table for Alpha Gpc Fatigue Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Alpha Gpc Fatigue Randomized Trial | Individual exercise tolerance is defined as the amount of physical exertion that can be sustained before task disengagement and can be increased through appropriate training strategies [,]. | 4 | Strasser Barbara (2026) | Dietary interventions interact with the perception of effort and enhance endurance performance: a brief narrative review |
| Alpha Gpc Fatigue Randomized Trial | We then integrate evidence on the ergogenic effects of various dietary interventions with existing knowledge on perception of effort, focusing on how these interventions may limit the development of fatigue during endurance exercise and thereby influence effort perception. | 4 | Strasser Barbara (2026) | Dietary interventions interact with the perception of effort and enhance endurance performance: a brief narrative review |
| Alpha Gpc Fatigue Randomized Trial | Such adjustments result in impaired time trial performance when perceived effort rises [], and improved performance when perceived effort is reduced []. | 4 | Strasser Barbara (2026) | Dietary interventions interact with the perception of effort and enhance endurance performance: a brief narrative review |
| Alpha Gpc Fatigue Randomized Trial | 1 2 3 4 5 1 1 Individual aerobic endurance capacity determines how long and at what intensity everyday activities, such as climbing stairs or gardening, as well as strenuous sports, including running, cycling, or swimming, can be performed []. | 4 | Strasser Barbara (2026) | Dietary interventions interact with the perception of effort and enhance endurance performance: a brief narrative review |
| Alpha Gpc Fatigue Randomized Trial | Most basic or translational researchers have to find the medical evidence of AD research from Aβ aggregation, phosphorylation of tau, enzyme assay such as AchEI or BACE, etc, whereas the others looked for the large scale screening multi-omics approach to find a target molecule from big data, sometimes presenting pre- or clinical neuropsychological tests, or PET imagings such as amyloid or tau. | 4 | Kim Manho (2025) | Current clinical trends in developing strategies for dementia disorders and the role of Korean Red Ginseng |
| Alpha Gpc Fatigue Randomized Trial | Lecanemab, on the other hand, has shown more promising results in clinical trials, with evidence suggesting it may help preserve cognitive function while also reducing pathological brain burden []. | 4 | Kim Manho (2025) | Current clinical trends in developing strategies for dementia disorders and the role of Korean Red Ginseng |
| Alpha Gpc Fatigue Randomized Trial | In conclusion, monoclonal antibodies represent a promising step forward in Alzheimer's treatment by addressing the core pathological features of the disease. | 4 | Kim Manho (2025) | Current clinical trends in developing strategies for dementia disorders and the role of Korean Red Ginseng |
| Alpha Gpc Fatigue Randomized Trial | [1] [2] [3] [4] [1] [2] [3] 3 Only a few years ago, new treatment of Alzheimer's disease (AD) has been approved by FDA, using the development of monoclonal antibody therapy. | 4 | Kim Manho (2025) | Current clinical trends in developing strategies for dementia disorders and the role of Korean Red Ginseng |
Source documents